Biocompatibles says Irinotecan beads active, safe

By Elaine Rigoli

Tampa, Fla., Sept. 12 - Biocompatibles International plc said preliminary data from its second drug-eluting bead program showed that in all 20 patients, a reduction in carcinoembryonic antigen of more than 50% was documented and in 15 patients, an objective tumor response at one month was observed.

Biocompatibles said the market opportunity for this product is up to $400 million and the potential market opportunity for the Irinotecan bead is larger.

The Surrey, U.K.-based medical technology company said it expects to start further clinical work in the Irinotecan drug-eluting bead program in the next few months.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.